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Abstract Medial temporal atrophy is a well-established
marker for Alzheimer’s disease (AD). However, due to
normal variation in the size of medial temporal structures
and variability in how radiologists interpret images, the use
of clinical reads in establishing the presence of pathologi-
cal atrophy is imprecise. A limitation of studies of mag-
netic resonance imaging (MRI) measures in AD is
diagnostic uncertainty as it can be unknown if pre- or early-
symptomatic subjects go on to develop AD and most
subjects do not undergo autopsy veriﬁcation of the diag-
nosis. In persons with or at-risk for AD due to fully-
penetrant autosomal dominant mutations in the PSEN1 and
APP genes, the diagnosis or future development of AD can
be predicted with essentially 100% accuracy. We used this
predictability to assess the ability of radiologists to detect
hippocampal atrophy (HA) in persons destined to develop
AD. Coronal T1-weighted MRI scans of 39 persons
demented from (n = 4) or at-risk for inheriting (n = 35)
PSEN1 or APP mutations were independently assessed by
two radiologists and the presence or absence of HA
determined. Of the 39 subjects, 26 were FAD mutation
carriers. Fifteen of 28 asymptomatic at-risk persons were
FAD mutation carriers and four of these were rated as
having atrophy for a sensitivity of 27% and a speciﬁcity of
85%. Among seven mildly affected yet non-demented
subjects, atrophy was detected in three and in the four
demented subjects HA was identiﬁed in two. Our results
suggest that radiologists’ ability to detect HA in persons in
whom the diagnosis of incipient AD is certain is sub-
optimal and quantitative MRI techniques or other biologi-
cal markers of the disease are needed.
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Progressive cerebral atrophy, and medial temporal lobe
atrophy in particular, has long been recognized as being
characteristic of Alzheimer’s disease (AD). The degree of
such atrophy can be subtle or absent in early and particu-
larly in presymptomatic disease but increases with disease
severity. There is signiﬁcant inter-individual variation in
the volume of medial temporal lobe structures that
increases with age and inter-observer reliability of judg-
ment of medial temporal lobe size is sub-optimal [16]. It
can therefore be challenging for a clinician to conclude
whether the brain magnetic resonance imaging (MRI) scan
of a given individual represents a normal degree of atrophy
or if it is suggestive of a pathological process such as AD.
A prior study showed that visual determination of medial
temporal lobe atrophy in persons with mild cognitive
impairment independently predicted progression to
dementia but there was signiﬁcant overlap between those
who progressed and those who did not [7]. Quantitative
volumetric techniques can be employed to differentiate
patients with AD from controls based on the sizes of
medial temporal lobe structures [6]. Such techniques,
however, have not yet made their way into mainstream
clinical neuroradiology and neurologists typically depend
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the degree to which a given brain size represents patho-
logical atrophy.
One of the challenges to ascertaining how well the
observed size of brain structures, as assessed visually by a
radiologist, relates to clinical diagnosis in early or pre-
symptomatic AD is difﬁculty in determining what the
pathological diagnosis is in each case. For a presymp-
tomatic population, subjects must be followed longitudi-
nally for many years to determine who will and will not
develop clinical symptoms. Even in established AD, the
diagnostic accuracy can be as low as 75% [8] and there-
fore, unless one obtains neuropathological veriﬁcation of
diagnosis, there is some uncertainty regarding the etiology
underlying the clinical symptoms. In autosomal dominantly
inherited AD of young onset (familial AD or FAD) due to
mutations in the PSEN1 and APP genes, the ultimate
development of AD can be predicted with essentially 100%
certainty. Persons at-risk for the inheritance of these
mutations therefore provide a model in which the sensi-
tivity of radiological assessment of brain atrophy to the
presence of incipient AD can be reliably tested.
In this study, two experienced neuroradiologists (authors
N.S. and W.P.) rated the T1-weighted structural MRI scans
of 39 demented (n = 4), mildly symptomatic (n = 7), or
asymptomatic (n = 28) members of 13 families carrying
known APP (n = 2) or PSEN1 (n = 11) mutations. Among
families with PSEN1 mutations, one had the L235V [5],
one the G206A [2], one an S212Y (unpublished, new
variant), and eight had the A431E substitution. The A431E
substitution in the PSEN1 gene represents a founder effect
originating in Jalisco State in Mexico [12, 17]. The two
families with APP mutations both had the V717I substi-
tution that has been described in diverse populations
worldwide [11]. Though the S212Y PSEN1 alteration has
not previously been reported, there is substantial evidence
for its pathogenicity. The single subject included in this
study with it was clinically affected by dementia and her
similarly affected brother (whose diagnosis of AD was
veriﬁed on autopsy) was also demonstrated to carry it.
Furthermore, an unaffected older sister was found not to
have inherited it.
Clinical status was deﬁned using the Clinical Dementia
Rating (CDR score, 0 = asymptomatic, 0.5 = mildly
symptomatic but not demented, 1 = mildly, 2 = moder-
ately, and 3 = severely demented) scale [10]. Subjects also
underwent comprehensive neuropsychological testing and
it was determined whether or not they met criteria for mild
cognitive impairment [13] using previously published
methods [15]. All demented and mildly symptomatic
subjects were mutation carriers. Of the seven mildly
symptomatic (CDR scores = 0.5) subjects, six met neu-
ropsychological criteria for mild cognitive impairment. Of
the 28 asymptomatic (CDR scores = 0) subjects, 15
carried pathogenic APP or PSEN1 mutations with the
remaining 13 subjects being non-mutation carrying family
members. One mutation carrier with a CDR score of 0 met
neuropsychological criteria for MCI. Chronological ages
ranged from 19 to 59. As age of onset can be consistent
within families with these genes, a family-speciﬁc age
relative to the age of typical dementia diagnosis (‘‘relative
age’’) was calculated for each subject. Relative ages varied
ranged from 35 years prior to 18 years after the typical age
for dementia diagnosis in their family.
All T1-weighted brain images were obtained in a uni-
form fashion on the same 1.5T Siemens Sonata scanner in
the sagittal plane using a 3-D MP-RAGE sequence
(TR = 1,900 ms, TE = 4.38 ms, TI = 1,100 ms, ﬂip
angle 15, voxel size of 1 9 1 9 1m m
3). Two radiolo-
gists, blinded to all genetic and clinical information,
independently rated atrophy of the right and left hippo-
campi on images reformatted in the coronal plane.
Hippocampi were judged as either being normal (0, hip-
pocampal height at the head to body level assessed as being
greater than 10 mm), or showing mild (1, 7–10 mm),
moderate (2, 5–7 mm), or severe (3, \5 mm) atrophy.
When asymmetry of the temporal horn was present,
hippocampal height and conﬁguration of the hippocampus
(loss of indentation of the head of the hippocampus, ﬂat-
tening of the body of the hippocampus, etc.) were used to
assess atrophy. This categorization was subsequently
collapsed such that hippocampal atrophy was judged as
being absent (0) or present (1, 2, 3 = 1). When the two
radiologists were discrepant, they met and discussed the
differences and made a consensus judgment as to whether
or not atrophy was present.
Of the four demented subjects, two were rated as having
no hippocampal atrophy (CDR scores of 2, see Fig. 1a).
One subject with a CDR score of 3 was rated as having
severe hippocampal atrophy bilaterally and one with a
CDR score of 1 was rated as having mild hippocampal
atrophy on the left side but not the right. Of the seven FAD
mutation carriers with CDR scores of 0.5, four were rated
as having no atrophy, one as having bilateral hippocampal
atrophy, and one each with right and left hippocampal
atrophy only (all mild). Of the 15 asymptomatic FAD
mutation carriers, 11 were rated as having no atrophy, three
had bilateral, and one had unilateral atrophy (all mild).
Among the 13 non-carriers, one was rated as having
bilateral (Fig. 1b) and one unilateral mild hippocampal
atrophy. Of note, these two subjects were not among the
oldest subjects in the cohort being between 30 and 40 years
of age (speciﬁc ages not given to protect conﬁdentiality). In
this study therefore, the sensitivity and speciﬁcity of hip-
pocampal atrophy for predicting FAD mutation status in
asymptomatic subjects was 27 and 85%, respectively.
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sitivity was 43% and in demented subjects it was 50%.
In this population in which the future development of
AD can be predicted with essentially 100% accuracy in
presymptomatic persons, visual detection of hippocampal
atrophy is an insensitive way of detecting early disease.
This might be expected considering the young age of some
subjects relative to the expected age of symptom onset.
However, among the 22 non-demented (CDR scores \1)
mutation carriers, the seven that were thought to have
atrophy were between 1 and 18 years prior to the estimated
age of disease diagnosis in their families. Among the four
mutation carriers that were within 5 years of their esti-
mated age of disease diagnosis, only one was thought to
have HA. As visual interpretation of HA in mildly symp-
tomatic mutation carriers (CDR scores = 0.5) had a
sensitivity of only 43%, neither clinical status nor age
therefore predicted the presence of HA well.
A prior quantitative study of brain volumes in young-
onset AD suggested that the pattern of gray matter loss can
differ from AD of older onset with young onset patients
having proportionally more atrophy of parietal and occip-
ital cortex than of medial temporal lobe structures [4].
Another quantitative study, however, demonstrated that
hippocampal atrophy does indeed occur in FAD and can be
detectable 3–5.5 years prior to clinically diagnosable dis-
ease [14]. Our ﬁnding that visual assessment of hippo-
campal volume is insensitive to early atrophy in persons
destined to develop FAD should therefore generalize, at
least to some extent, to late onset AD.
Other biological markers such as FDG and PIB-PET
scanning [3] and biochemical measurements in cerebro-
spinal ﬂuid (CSF measurements of Ab42 and tau)[ 9] also
have great promise in improving our ability to detect AD at
early presymptomatic stages. Though not readily available
to most clinicians, quantitative volumetric MRI measure-
ments are more sensitive and predictive of subsequent
clinical course in early AD [1] and therefore superior to
visual inspection in this regard. Increased efforts are being
made to increase the availability of such tools to the
practitioner to augment their ability to diagnose AD early
in the clinic.
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